

## Part VI: Summary of the risk management plan Salbutamol Neutec 2.5 mg nebuliser solution (salbutamol sulphate)

This is a summary of the risk management plan (RMP) for Salbutamol Neutec 2.5 mg nebulizer solution. The RMP details important risks of Salbutamol Neutec 2.5 mg nebulizer solution, how these risks can be minimised, and how more information will be obtained about Salbutamol Neutec 2.5 mg nebulizer solution 's risks and uncertainties (missing information).

Salbutamol Neutec 2.5 mg nebulizer solution 's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Salbutamol Neutec 2.5 mg nebulizer solution should be used.

### I. The medicine and what it is used for

Salbutamol Neutec 2.5 mg nebulizer solution is authorised for symptomatic treatment of acute reversible airway obstruction in patients with asthma or in patients with severe chronic obstructive pulmonary disease (COPD) (see SmPC for the full indication). It contains salbutamol sulphate as the active substance, and it is given by inhalation.

### II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Salbutamol Neutec 2.5 mg nebulizer solution, together with measures to minimise such risks and the proposed studies for learning more about Salbutamol Neutec 2.5 mg nebulizer solution's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals.
- Important advice on the medicine's packaging.
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly.
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken, as necessary. These measures constitute *routine pharmacovigilance activities*.

#### II.A List of important risks and missing information

Important risks of Salbutamol Neutec are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken by inhalation. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Salbutamol Neutec. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the longterm use of the medicine).

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

### ***II.B Summary of important risks***

The safety information in the proposed Product Information is aligned to the reference medicinal product.

### ***II.C Post-authorisation development plan***

#### **II.C.1 Studies which are conditions of the marketing authorisation**

Not applicable

#### **II.C.2 Other studies in post-authorisation development plan**

Not applicable